Exenatide and the treatment of patients with Parkinson’s disease-Reference-Cited by-同舟云学术

Exenatide and the treatment of patients with Parkinson’s disease

Published:2013-05-20 Issue:6 Volume:123 Page:2730-2736
ISSN:0021-9738
Container-title:Journal of Clinical Investigation
language:en
Short-container-title:J. Clin. Invest.

Author:

Aviles-Olmos Iciar,Dickson John,Kefalopoulou Zinovia,Djamshidian Atbin,Ell Peter,Soderlund Therese,Whitton Peter,Wyse Richard,Isaacs Tom,Lees Andrew,Limousin Patricia,Foltynie Thomas

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Reference25 articles.

1. Why have we failed to achieve neuroprotection in Parkinson's disease?

2. Parkinson's disease, insulin resistance and novel agents of neuroprotection

3. Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Sulfonylurea-Treated Patients With Type 2 Diabetes

4. Effects of Exenatide (Exendin-4) on Glycemic Control and Weight Over 30 Weeks in Metformin-Treated Patients With Type 2 Diabetes

Cited by 378 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Beyond insulin: The Intriguing role of GLP-1 in Parkinson's disease;European Journal of Pharmacology;2024-11

2. Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Parkinson's Disease in Patients with Type 2 Diabetes: A Population‐Based Cohort Study;Movement Disorders;2024-08-27

3. Glucagon-like peptide-1 class drugs show clear protective effects in Parkinson's and Alzheimer's disease clinical trials: A revolution in the making?;Neuropharmacology;2024-08

4. Current Therapeutic Options and Repurposed Drugs for Neurodegeneration;Advances in Diagnostics and Immunotherapeutics for Neurodegenerative Diseases;2024-07-28

5. Incretin-Based Multi-Agonist Peptides Are Neuroprotective and Anti-Inflammatory in Cellular Models of Neurodegeneration;Biomolecules;2024-07-19